Documento de consenso sobre enfermedad pulmonar obstructiva crónica en Andalucía

Referencias bibliográficas

• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of COPD. Updated 2007. Disponible en: http://www.goldcopd.org/
• Guía de práctica clínica de diagnóstico y tratamiento de la Enfermedad Pulmonar Obstructiva Crónica. SEPARALAT, 2007. www.separ.es. Último acceso: 16/11/07.
• Sobradillo V, Miravitlles M, Jiménez CA, Gabriel R, Viejo JL, Masa JF, Fernández-Fau L, Villasante C. Estudio IBERPOC en Espana: prevalencia de síntomas respiratorios habituales y de limitación crónica al flujo aéreo. Arch Bronconeumol 1999; 35(4): 159-66.
• López-Campos Bodineau JL, Fernández Guerra J, Lara Blanquer A, Perea-Milla López E, Moreno L, Cebrián Gallardo JJ, García Jiménez JM. Análisis de los ingresos por enfermedad pulmonar obstructiva crónica en Andalucía, año 2000. Arch Bronconeumol 2002; 38(10): 473-8.
• Fernández Guerra J, García Jiménez JM, Marín Sánchez F. Enfermedad pulmonar obstructiva crónica (EPOC). Tratamiento de la fase estable. En: JG Soto Campos. Manual de diagnóstico y terapéutica en Neumología. Madrid: Ergon, 2006; 279-90.
• Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977; 1(6077): 1645-8.
• Pearson MG, Calverley PMA, Clinical and laboratory assessment. In: Calverley PMA, Pride NB, Eds. Chronic Obstructive Pulmonary disease. London: Chapman and Hall, 1994.
• Wolkove N, Dajczman E, Colacone A, Kreisman H. The relationship between pulmonary function and dyspnea in obstructive lung disease. Chest 1989; 96(6): 1247-51.
• Fletcher CM, Elmes PC, Fairbairn AS, Wood CH. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J 1959; 2(5147): 257-66.
• Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350(10): 1005-12.
• Klein JS, Gamsu G, Webb WR, Golden JA, Müller NL. High-resolution CT diagnosis of emphysema in symptomatic patients with normal chest radiographs and isolated low diffusing capacity. Radiology 1992; 182(3): 817-21.
• Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, Weinmann G, Wood DE; National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volumereduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348(21): 2059-73.
• Fernández Guerra J, García Jiménez JM, Perea-Milla López E, Cebrián Gallardo JJ, Mora Ruiz E, Moreno Arrastio LF. Gasometria arterial en pacientes con enfermedad pulmonar obstructiva cronica estable segun los valores de la espirometria. Med Clin (Barc) 2006; 127(3): 90-2.
• Ferrer M, Alonso J, Prieto L, Plaza V, Monsó E, Marrades R, Aguar MC, Khalaf A, Antó JM. Validity and reliability of the St George’s Respiratory Questionnaire after adaptation to a different language and culture: the Spanish example. Eur Respir J 1996; 9(6): 1160-6.
• Güell R, Casan P, Sangenís M, Morante F, Belda J, Guyatt GH. Quality of life in patients with chronic respiratory disease: the Spanish version of the Chronic Respiratory Questionnaire (CRQ). Eur Respir J 1998; 11(1): 55-60.
• Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting. Bull World Health Organ 1997; 75(5): 397-415.
• American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168(7): 818-900.
• Vidal R, Blanco I, Casas F, Jardí R, Miravitlles M y Comité del Registro Nacional de Pacientes con Déficit de de Alfa-1-Antitripsina. Diagnóstico y tratamiento del déficit de alfa-1-antitripsina. Arch Bronconeumol 2006; 42(12): 645-59.
• Peña VS, Miravitlles M, Gabriel R, Jiménez-Ruiz CA, Villasante C, Masa JF, Viejo JL, Fernández-Fau L. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest 2000; 118(4): 981-9.
• Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA Jr, Enright PL, Kanner RE, O’Hara P, Owens GR, Scanlon PD, Tashkin DP, Wise RA. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272(19): 1497-505.
• Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000; 161(2 Pt 1): 381-90.
• Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE; Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005; 142(4): 233-9.
• Marlow SP, Stoller JK. Smoking cessation. Respir Care 2003; 48(12): 1238-54.
• Jiménez-Ruiz CA, de Granda Orive JI, Solano Reina S, Carrión Valero F, Romero Palacios P, Barrueco Ferrero M; SEPAR. Recomendaciones para el tratamiento del tabaquismo. Arch Bronconeumol 2003; 39(11): 514-23.
• Bednarek M, Gorecka D, Wielgomas J, Czajkowska-Malinowska M, Regula J, Mieszko-Filipczyk G, Jasionowicz M, Bijata-Bronisz R, Lempicka-Jastrzebska M, Czajkowski M, Przybylski G, Zielinski J. Smokers with airway obstruction are more likely to quit smoking. Thorax 2006; 61(10): 869-73.
• Górecka D, Bednarek M, Nowiski A, Puciska E, Goljan-Geremek A, Zieliski J. Diagnosis of airflow limitation combined with smoking cessation advice increases stop-smoking rate. Chest 2003; 123(6): 1916-23.
• Jiménez-Ruiz CA, Masa F, Miravitlles M, Gabriel R, Viejo JL, Villasante C, Sobradillo V. Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD. Chest 2001; 119(5): 1365-70.
• Kunik ME, Roundy K, Veazey C, Souchek J, Richardson P, Wray NP, Stanley MA. Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest 2005; 127(4): 1205-11.
• Wagena EJ, Zeegers MP, van Schayck CP, Wouters EF. Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary disease. Drug Saf 2003; 26(6): 381-403.
• Rigotti NA, Munafo MR, Stead LF. Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst Rev 2007; (3): CD001837.
• Van der Meer RM, Wagena EJ, Ostelo RW, Jacobs JE, van Schayck CP. Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2003; (2): CD002999.
• Tashkin D, Kanner R, Bailey W, Buist S, Anderson P, Nides M, Gonzales D, Dozier G, Patel MK, Jamerson B. Smoking cessation in patients with chronic obstructive pulmonary disease: a doubleblind, placebo-controlled, randomised trial. Lancet 2001; 357(9268): 1571-5.
• Wu P, Wilson K, Dimoulas P, Mills EJ. Effectiveness of smoking cessation therapies: a systematic review and metaanalysis. BMC Public Health 2006; 6: 300.
• Sestini P, Renzoni E, Robinson S, Poole P, Ram FS. Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002; (4): CD001495.
• National Institute for Clinical Excellence. Chronic obstructive pulmonary disease Management of chronic obstructive Pulmonary disease in adults in primary and secondary care. www.nice.org.uk/CG012NICEguideline. Último acceso: 16/11/07.
• Sin DD, McAlister FA, Man SF, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003; 290(17): 2301-12.
• Stockley RA, Whitehead PJ, Williams MK. Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis. Respir Res 2006; 7: 147.
• Barr RG, Bourbeau J, Camargo CA, Ram FS. Tiotropium for stable chronic obstructive pulmonary disease: A metaanalysis. Thorax 2006; 61(10): 854-62.
• Kerstjens HA, Bantje TA, Luursema PB, Sinninghe Damste HE, de Jong JW, Lee A, Wijker SP, Cornelissen PJ. Effects of shortacting bronchodilators added to maintenance tiotropium therapy. Chest 2007; 132(5): 1493-9.
• Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Korducki L, Cornelissen PJ; Dutch/Belgian Tiotropium Study Group. Improved health outcomes in patients with COPD during 1 yr’s treatment with tiotropium. Eur Respir J 2002; 19(2): 209-16.
• Barr RG, Bourbeau J, Camargo CA, Ram FS. Tiotropium for stable chronic obstructive pulmonary disease: A metaanalysis. Thorax 2006; 61(10): 854-62.
• Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23(6): 932-46.
• Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O’Donnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, Zamel N, FitzGerald M; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasonesalmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 146(8): 545-55.
• Van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A, Cornelissen PJ. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006; 129(3): 509-17.
• Yang IA, Fong KM, Sim EH, Black PN, Lasserson TJ. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007; (2): CD002991.
• Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320(7245): 1297-303.
• Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Longterm effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353(9167): 1819-23.
• Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343(26): 1902-09.
• Soriano JB, Sin DD, Zhang X, Camp PG, Anderson JA, Anthonisen NR, Buist AS, Burge PS, Calverley PM, Connett JE, Petersson S, Postma DS, Szafranski W, Vestbo J. A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest 2007; 131(3): 682-89.
• Calverley PM, Burge PS, Spencer S, Anderson JA, Jones PW. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003; 58(8): 659-64.
• Van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med 2002; 166(10): 1358-63.
• Schermer TR, Hendriks AJ, Chavannes NH, Dekhuijzen PN, Wouters EF, van den Hoogen H, van Schayck CP, van Weel C. Probability and determinants of relapse after discontinuation of inhaled corticosteroids in patients with COPD treated in general practice. Prim Care Respir J 2004; 13(1): 48-55.
• Jarad NA, Wedzicha JA, Burge PS, Calverley PM. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respir Med 1999; 93(3): 161-6.
• Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, Shah T. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166(8): 1084-91.
• Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C; TRial of Inhaled STeroids ANd long-acting beta2 agonists study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361(9356): 449-456.
• Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21(1): 74-81.
• Hanania NA, Darken P, Horstman D, Reisner C, Lee B, Davis S, Shah T. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003; 124(3): 834-43.
• Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22(6): 912-19.
• Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176(2): 162-166.
• Decramer M, Rutten-van Mölken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R, van Schayck CP, Olivieri D, Del Donno M, De Backer W, Lankhorst I, Ardia A. Effects of Nacetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005; 365(9470): 1552-60.
• Poole PJ, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 3: CD001287.
• Seersholm N, Wencker M, Banik N, Viskum K, Dirksen A, KokJensen A, Konietzko N. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J 1997; 10(10): 2260-3.
• Wencker M, Fuhrmann B, Banik N, Konietzko N; Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Chest 2001; 119(3): 737-44.
• Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1998; 158(1): 49-59.
• Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest 2000; 118(5): 1480-5.
• Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981; 1(8222): 681-6.
• Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980; 93(3): 391-8.
• Cranston JM, Crockett AJ, Moss JR, Alpers JH. Domiciliary oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; (4): CD001744.
• Ström K, Odeberg H, Andersson AC, Boe J, Singer J, Svensson G. S-erythropoietin levels decrease in patients with chronic hypoxia starting domiciliary oxygen therapy. Eur Respir J 1991; 4(7): 820-3.
• Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Pelletier A. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1985; 131(4): 493-8.
• Zieliƒski J, Tobiasz M, Hawry∏kiewicz I, Sliwiƒski P, Pa∏asiewicz G. Effects of long-term oxygen therapy on pulmonary hemodynamics in COPD patients: a 6-year prospective study. Chest 1998; 113(1): 65-70.
• Ringbaek TJ, Viskum K, Lange P. Does long-term oxygen therapy reduce hospitalisation in hypoxaemic chronic obstructive pulmonary disease? Eur Respir J 2002; 20(1): 38-42.
• Farrero Muñoz E. Oxigenoterapia crónica domiciliaria. En: Güell Rous R, de Lucas Ramos P. Tratado de rehabilitación respiratoria. Barcelona: Ars XXI de comunicación, 2005; 291-301.
• Górecka D, Gorzelak K, Sliwiƒski P, Tobiasz M, Zieliƒski J. Effect of long-term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia. Thorax 1997; 52(8): 674-9.
• Sánchez Agudo L, Cornudella R, Estopá Miró R, Molinos Martín L, Servera Pieras E. Normativa para la indicacion y empleo de la oxigenoterapia continuada domiciliaria (OCD). Normativas SEPAR. Arch Bronconeumol 1998; 34(2): 87-94.
• Normativa sobre la gasometría arterial. Grupo de Trabajo de la SEPAR para la práctica de la gasometría arterial. Arch Bronconeumol 1998; 34(3): 142-53.
• West JB. Intercambio gaseoso. En: West JB. Fisiopatología pulmonar. 4ª Ed. Madrid: Ed Panamericana, 1994; 27-46.
• León Jiménez A, López-Campos JL, Casas F, Jurado B, Cano S, Arnedillo A, Muñoz L, López S. Factors related to variability in long-term oxygen therapy prevalence. Int J Tuberc Lung Dis 2006; 10(1): 110-4.
• Chaouat A, Weitzenblum E, Kessler R, Charpentier C, Enrhart M, Schott R, Levi-Valensi P, Zielinski J, Delaunois L, Cornudella R, Moutinho dos Santos J. A randomized trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease patients. Eur Respir J 1999; 14(5): 1002-8.
• McDonald CF, Blyth CM, Lazarus MD, Marschner I, Barter CE. Exertional oxygen of limited benefit in patients with chronic obstructive pulmonary disease and mild hypoxemia. Am J Respir Crit Care Med 1995; 152(5 Pt 1): 1616-9.
• Wijkstra PJ, Lacasse Y, Guyatt GH, Casanova C, Gay PC, Meecham Jones J, Goldstein RS. A meta-analysis of nocturnal noninvasive positive pressure ventilation in patients with stable COPD. Chest 2003; 124(1): 337-43.
• Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation-a consensus conference report. Chest 1999; 116(2): 521-34.
• Alfageme Michavila I, Reyes Núñez N, Merino Sánchez M. Vacunación en el enfermo respiratorio. Neumosur 2005; 17 (4): 259-64.
• Alfageme I, Vazquez R, Reyes N, Muñoz J, Fernández A, Hernandez M, Merino M, Perez J, Lima J. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006; 61(3):189-95.
• Hui KP, Hewitt AB. A simple pulmonary rehabilitation program improves health outcomes and reduces hospital utilization in patients with COPD. Chest 2003; 124(1): 94-7.
• Hakim AA, Petrovitch H, Burchfiel CM, Ross GW, Rodriguez BL, White LR, Yano K, Curb JD, Abbott RD. Effects of walking on mortality among nonsmoking retired men. N Engl J Med 1998; 338(2): 94-9.
• Paffenbarger RS Jr, Hyde RT, Wing AL, Hsieh CC. Physical activity, all-cause mortality, and longevity of college alumni. N Engl J Med 1986; 314(10): 605-13.
• Lacasse Y, Wong E, Guyatt GH, King D, Cook DJ, Goldstein RS. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. Lancet 1996; 348(9035): 1115-9.
• Salman GF, Mosier MC, Beasley BW, Calkins DR. Rehabilitation for patients with chronic obstructive pulmonary disease: metaanalysis of randomized controlled trials. J Gen Intern Med 2003; 18(3): 213-21.
• Lacasse Y, Brosseau L, Milne S, Martin S, Wong E, Guyatt GH, Goldstein RS. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002; (3): CD003793.
• Troosters T, Casaburi R, Gosselink R, Decramer M. Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172(1): 19-38.
• Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, Carone M, Celli B, Engelen M, Fahy B, Garvey C, Goldstein R, Gosselink R, Lareau S, MacIntyre N, Maltais F, Morgan M, O’Donnell D, Prefault C, Reardon J, Rochester C, Schols A, Singh S, Troosters T; ATS/ERS Pulmonary Rehabilitation Writing Committee. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006; 173(12): 1390-413.
• Lake FR, Henderson K, Briffa T, Openshaw J, Musk AW. Upperlimb and lower-limb exercise training in patients with chronic airflow obstruction. Chest 1990; 97(5): 1077-82.
• Bernard S, Whittom F, Leblanc P, Jobin J, Belleau R, Bérubé C, Carrier G, Maltais F. Aerobic and strength training in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159(3): 896-901.
• Ortega F, Toral J, Cejudo P, Villagomez R, Sánchez H, Castillo J, Montemayor T. Comparison of effects of strength and endurance training in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166(5): 669-74.
• Hernández MT, Rubio TM, Ruiz FO, Riera HS, Gil RS, Gómez JC. Results of a home-based training program for patients with COPD. Chest 2000; 118(1): 106-14.
• Rubio Sánchez JM, Jurado Gámez B, Mayordomo Riera F, Muñoz Cabrera L. EPOC: influencia sobre la disnea de un programa de ejercicio domiciliario. Neumosur 2006; 18 (2): 69-77.
• Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Antó JM. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax 2006; 61(9): 772-8.
• Giner Donaire J, Morante Vélez F. Educación del paciente respiratorio crónico. En: Güel R, de Lucas P. Rehabilitación Respiratoria. Madrid: Medical & Marketing Communications, 1999; 107-120. Snider GL. Reduction pneumoplasty for giant bullous emphysema. Implications for surgical treatment of nonbullous emphysema. Chest 1996; 109(2): 540-8.
• National Emphysema Treatment Trial Research Group. Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med 2001; 345(15): 1075-83.
• Orens JB, Estenne M, Arcasoy S, Conte JV, Corris P, Egan JJ, Egan T, Keshavjee S, Knoop C, Kotloff R, Martinez FJ, Nathan S, Palmer S, Patterson A, Singer L, Snell G, Studer S, Vachiery JL, Glanville AR; Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the Internacional Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25(7): 745-55.
• Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117(5 Suppl 2): 398S-401S.
• Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60(11): 925-31.
• Díaz Lobato S, González Lorenzo F, Gómez Mendieta MA, Mayoralas Alises S, Martín Arechabala I, Villasante Fernández-Montes C. Evaluacion de un programa de hospitalizacion domiciliaria en pacientes con EPOC agudizada. Arch Bronconeumol 2005; 41(1): 5-10.
• Casas A, Troosters T, Garcia-Aymerich J, Roca J, Hernández C, Alonso A, del Pozo F, de Toledo P, Antó JM, Rodríguez-Roisín R, Decramer M; members of the CHRONIC Project. Integrated care prevents hospitalisations for exacerbations in COPD patients. Eur Respir J 2006; 28(1): 123-30.
• Rodríguez-Roisin R. COPD exacerbations.5: management. Thorax 2006; 61(6): 535-44.
• McCrory DC, Brown CD. Anti-cholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002; (4): CD003900.
• Turner MO, Patel A, Ginsburg S, FitzGerald JM. Bronchodilator delivery in acute airflow obstruction. A meta-analysis. Arch Intern Med 1997; 157(15): 1736-44.
• De Jong YP, Uil SM, Grotjohan HP, Postma DS, Kerstjens HA, van den Berg JW. Oral or IV Prednisolone in the Treatment of COPD Exacerbations: A Randomized, Controlled, Double-blind Study. Chest 2007; 132(6): 1741-7.
• Gunen H, Hacievliyagil SS, Yetkin O, Gulbas G, Mutlu LC, In E. The role of nebulised budesonide in the treatment of exacerbations of COPD. Eur Respir J 2007; 29(4): 660-7.
• Alvarez F, Bouza E, García-Rodríguez JA, Mayer MA, Mensa J, Monsó E, Nodar E, Picazo JJ, Sobradillo V, Torres A; Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Uso de antimicrobianos en la exacerbación de la enfermedad pulmonar obstructiva crónica. Arch Bronconeumol 2002; 38(2): 81-9.
• Sociedad Española de Quimioterapia (SEQ); Sociedad Española de Neumología y Cirugía Torácica (SEPAR); Sociedad Española de Medicina de Urgencias y Emergencias (SEMES); Sociedad Española de Medicina General (SEMG); Sociedad Española de Medicina Rural y Generalista (SEMERGEN); Sociedad Española de Medicina Interna (SEMI). Tercer documento de consenso sobre el uso de antimicrobianos en la agudización de la enfermedad pulmonar obstructiva crónica Rev Esp Quimioter 2007; 20(1): 93-105.
• O’Donnell DE, Aaron S, Bourbeau J, Hernandez P, Marciniuk DD, Balter M, Ford G, Gervais A, Goldstein R, Hodder R, Kaplan A, Keenan S, Lacasse Y, Maltais F, Road J, Rocker G, Sin D, Sinuff T, Voduc N. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. Can Respir J 2007; 14(Suppl B): 5B-32B.
• Fernández Guerra J, López-Campos Bodineau JL, Perea-Milla López E, Pons Pellicer J, Rivera Irigoin R, Moreno Arrastio LF. Metaanálisis de la eficacia de la ventilación no invasiva en la exacerbación aguda de la enfermedad pulmonar obstructiva crónica. Med Clin (Barc) 2003; 120(8): 281-6.
• British Thoracic Society Standards of Care Committee. Non-invasive ventilation in acute respiratory failure. Thorax 2002; 57(3): 192-211.
• Mehta S, Hill NS. Noninvasive ventilation. Am J Respir Crit Care Med 2001; 163(2): 540-77.
• López-Campos JL, García Polo C, León Jiménez A, Arnedillo A, González-Moya E, Fenández Berni JJ. Staff training influence on non-invasive ventilation outcome for acute hypercapnic respiratory failure. Monaldi Arch Chest Dis 2006; 65(3): 145-51.
• Confalonieri M, Garuti G, Cattaruzza MS, Osborn JF, Antonelli M, Conti G, Kodric M, Resta O, Marchese S, Gregoretti C, Rossi A; Italian noninvasive positive pressure ventilation (NPPV) study group. A chart of failure risk for noninvasive ventilation in patients with COPD exacerbation. Eur Respir J 2005; 25(2): 348-55.
• León Jiménez A (coord.). Enfermedad pulmonar obstructiva crónica: proceso asistencial integrado. 2ª Ed. Sevilla: Consejería de Salud, 2007.